Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials

  • the UK Dermatology Clinical Trials Network

    Research output: Contribution to journalReview articlepeer-review

    Original languageEnglish
    Pages (from-to)1048-1059
    Number of pages12
    JournalClinical and Experimental Dermatology
    Volume47
    Issue number6
    DOIs
    Publication statusPublished (VoR) - Jun 2022

    Funding

    The UK DCTN thanks the BAD for its sustained support over the last 20 years and all of the UK DCTN individual members including patients and those who serve on its committees (see Appendix) who give their time freely to support the network. The UK DCTN is a registered UK charity (number 1115745) and is subject to Charity Commission rules. The network infrastructure is funded by the BAD and the University of Nottingham, with contribution in kind and donations from its members. The network also receives some funding for continuing support and dissemination from successful applications. The network does not accept funding from the pharmaceutical industry or other for-profit organizations. Learning points The UK DCTN is a democratic network that strives to support high-quality clinical trials in dermatology. Patients are and always have been at the heart of the network. Clinical trial suggestions come from the network membership. Trial prioritization follows a process starting with an outline vignette that is heard by a steering group. The network directly supports the development of prioritized trial suggestions by means of surveys, expert critique and by directly funding feasibility studies. The output of UK DCTN has shown what is possible by working collaboratively across professional boundaries. The UK DCTN is a democratic network that strives to support high-quality clinical trials in dermatology. Patients are and always have been at the heart of the network. Clinical trial suggestions come from the network membership. Trial prioritization follows a process starting with an outline vignette that is heard by a steering group. The network directly supports the development of prioritized trial suggestions by means of surveys, expert critique and by directly funding feasibility studies. The output of UK DCTN has shown what is possible by working collaboratively across professional boundaries.

    Fingerprint

    Dive into the research topics of 'Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials'. Together they form a unique fingerprint.

    Cite this